Nursing care
Long-Acting Injectable Antipsychotics: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 5 min read · Updated September 2026
Short answer
Long-acting injectable antipsychotics are given by deep intramuscular injection every two to twelve weeks, depending on the drug, for patients whose psychosis relapses once oral tablets stop. The interval is the safeguard: a missed dose is not a missed tablet, it is the start of relapse. Nurses track the due date as closely as the mental state.
Why this drug and not another
Long-acting injectables exist for one problem: non-adherence that leads to relapse. A patient who does well on olanzapine or paliperidone tablets but stops taking them within weeks of discharge is the typical candidate. The oral drug worked; the daily decision to take it did not.
Choosing depot over oral is a clinical decision made with the patient, not something a nurse decides alone, but the reasoning is worth knowing. Depot formulations remove the daily choice point. Plasma levels stay steadier, which also reduces the peak-and-trough pattern that worsens some side effects. The trade-off is that once injected, the drug cannot be withdrawn quickly if intolerance appears, so a short oral trial usually precedes the switch to injectable form.
Administration and timing
Administration is deep intramuscular, most often gluteal or deltoid depending on the specific agent, using Z-track technique to prevent leakage into subcutaneous tissue. The dosing interval ranges from every two weeks to every twelve, and it is fixed to that specific drug, not a range the nurse can adjust.
This is where the exam angle sits: the missed appointment is the relapse. Unlike a missed oral dose, which the patient can simply take late, a missed injection means falling plasma levels over days to weeks, often before any visible symptom returns. Nursing follow-up means confirming the next appointment before the patient leaves, flagging no-shows within days rather than waiting for a crisis presentation, and never treating a late injection as a minor scheduling issue.
Monitoring parameters
Baseline and ongoing monitoring mirrors the oral form of the drug: weight, waist circumference, fasting glucose, and lipid panel for the metabolic-risk agents, plus an ECG where the drug carries QT prolongation risk. Because the depot cannot be stopped instantly, baseline assessment before the first injection carries more weight than with an oral start.
After each injection, observe the site for firmness, redness, or a lump that could indicate inadvertent subcutaneous deposit, which slows and alters absorption. Extrapyramidal symptoms, sedation, and akathisia are assessed at each visit using the same tools as for oral antipsychotics, since steady-state levels mean side effects can persist across the full interval rather than fluctuating with a daily dose.
Adverse effects to report
Report new or worsening extrapyramidal symptoms: rigidity, tremor, dystonia, or the restless pacing of akathisia, which patients often describe as an inability to sit still rather than naming it. Neuroleptic malignant syndrome remains a rare but reportable emergency, marked by rigidity, hyperthermia, autonomic instability, and altered consciousness.
Injection-site reactions, sterile abscess, or unexpected pain out of proportion to a normal intramuscular injection should be reported and documented, since they can affect future site choice. Any post-injection delirium or sedation syndrome, seen specifically with olanzapine pamoate, requires the mandatory observation period after that particular injection and immediate reporting of confusion, sedation, or dizziness during it.
Contraindications and cautions
Contraindications largely follow the oral form of each specific antipsychotic: known hypersensitivity, severe CNS depression, and caution in dementia-related psychosis due to increased mortality risk in older adults. Hepatic and renal impairment may require dose adjustment or a longer interval rather than an outright contraindication.
Because the depot persists in the body for weeks, any contraindication that emerges after injection cannot be reversed by stopping the drug. This is why a short oral trial of the same medication is standard practice before the first injectable dose, allowing intolerance or hypersensitivity to surface while the drug can still be discontinued quickly.
Teaching points the exam tests
NCLEX questions on this class usually test whether the candidate understands that adherence to the injection schedule, not adherence to a daily tablet, is now the safety issue. Expect a scenario where a patient misses or delays an appointment, and the correct action is to schedule the injection as soon as possible and monitor closely for early relapse signs, not to wait for the next routine visit.
Teaching points for the patient mirror this: know the exact interval for your specific drug, keep the appointment even if feeling well, and understand that feeling well is the medication working, not a reason to stop. Site rotation, expected mild soreness versus reportable site reactions, and the fact that oral supplementation may be used only during an initial loading phase for certain agents are also common exam content.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our mental health practice questions are the closest set to what this page covers.
Common questions
Can a patient switch straight from tablets to the depot injection?
Usually yes, but most protocols require a brief period of oral overlap or a documented oral trial first to confirm the patient tolerates that specific antipsychotic. The exact overlap period depends on the drug; some require oral supplementation for the first few weeks until steady state is reached.
What do you do if a patient misses their injection date?
Contact the patient and reschedule as soon as possible rather than waiting for the next routine date. Depending on how much time has passed, some protocols require restarting an oral supplement or the initial loading schedule, so check the specific product guidance.
Why is olanzapine pamoate given differently from other long-acting injectables?
It carries a risk of post-injection delirium and sedation syndrome if any drug enters the bloodstream too quickly, so patients must be observed in a healthcare setting for a set period after each injection and monitored for sedation or confusion before being allowed to leave.
Do long-acting injectables cause fewer side effects than oral antipsychotics?
Not necessarily fewer, but often steadier. Avoiding the peaks and troughs of daily oral dosing can smooth out some side effects, but the same metabolic, extrapyramidal, and cardiac risks associated with the oral drug still apply and still require monitoring.
More on mental health